Global Dysmenorrhea Treatment Market – Industry Trends and Forecast to 2030

Global Dysmenorrhea Treatment Market, By Type (Primary Dysmenorrhea and Secondary Dysmenorrhea), Treatment (Hormonal Therapy, Pain Reliever, Surgery and Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.

Dysmenorrhea Treatment Market Analysis and Size

The dysmenorrhea treatment market is expanding as a result two primary key factors such as rising consumer awareness of dysmenorrhea therapy and the low price of over-the-counter drugs. As per the article published in the Women's Health Concern and British Menopause Society in December 2020, around 80% of dysmenorrhea women experience period pain at some stage in their lifetime. The launch of several new products for treating the pain related with primary and secondary dysmenorrhea is also pushing the market.

Data Bridge Market Research analyses a growth rate in the dysmenorrhea treatment market in the forecast period 2023-2030. The expected CAGR of dysmenorrhea treatment market is tend to be around 8.8% in the mentioned forecast period. The market was valued at USD 5937.8 million in 2022, and it would grow upto USD 11658.88 million by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Dysmenorrhea Treatment Market Scope and Segmentation

Market Definition

Dysmenorrhea is a type of condition that is characterized by painful periods and menstrual cramps. The condition occurs with unbearable pain occurs during menstruation in females. Symptoms typically last less than three days; the pain is generally in the pelvis or lower abdomen. The pain typically occurs 1 or 2 days before the menstrual bleeding starts and is usually felt in the lower abdomen area, thighs and back. The severity of the pain could vary and can also be stayed for 12 to 72 hours. The most common symptoms of dysmenorrhea are fatigue, diarrhoea, mood swings.

Global Dysmenorrhea Treatment Market Dynamics

Drivers

• Increasing Symptoms of Period Pain

As per the article published in the Women's Health Concern and British Menopause Society in December 2020, around 80% of dysmenorrhea women experience period pain at some stage in their lifetime. In about 40% of women, period pain is accompanied by premenstrual symptoms, such as bloating, swollen stomach, tender breasts, lack of concentration, mood swings, clumsiness, and tiredness. This boosts the market growth.

• Growing Research Studies About The Disease

According to the study titled "Fixed-Dose Combination of NSAIDs and Spasmolytic Agents in the Treatment of Different Types of Pain - A Practical Review", published in July 2021, many combinations of non-steroidal anti-inflammatory drugs (NSAIDs) and spasmolytics have been developed and tested, indicating a huge potential for future research to develop modern, effective combinations and search for new indications for the existing fixed-dose combination drugs for the treatment of dysmenorrhea.

Opportunities

• Increasing Launch of New Products

The launch of numerous new products for treating pain related with primary and secondary dysmenorrhea is also boosting the studied market. For instance, in September 2021, Myovant Sciences and Pfizer Inc. recieved the approval from U.S. FDA for the review of a supplemental New Drug Application (sNDA) for MYFEMBREE (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg) to manage moderate to severe pain associated with endometriosis. Thus, these several launches create much market opportunities.

• Rising Start-up Launches For Reproductive Health

Several start-ups have been launched by various organizations, leading to market growth. For instance, Gynica is a FemTech startup based in Israel. It is mainly responsible for the manufacturing of cannabis-based treatments for women's reproductive health. Gynica is a medical firm which is focused on studying and developing marijuana treatments for several gynecological disorders and symptoms. They are members of Station F's FemTech Cohort. This creates more opportunity in the market.

Restraints/Challenges

The high cost of care will hinder the market's growth rate during the forecast period of 2022-2030. Lack of public awareness and inadequate reimbursement policies may impede and impede market expansion during the projection period of 2022-2030.

Moreover, challenges related with long-term care and other side effects and issues, the high morbidity of menstrual cramps because of insufficient treatments, and traditional family values are projected to decrease the growth of the dysmenorrhea treatment market.

This global dysmenorrhea treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global dysmenorrhea treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Dysmenorrhea Treatment Market

COVID-19 has impacted the emotional and mental health of the people majorly. It has been witnessed that periods of stress and psychological distress can affect a woman’s menstrual health. The severe changes in menstrual cycles can lead to higher episodes of dysmenorrhea, considerably impacting the market. As per the study titled "The Impact of the COVID-19 Pandemic on Women’s Reproductive Health", published in March 2021, 46% of women reported a change in their menstrual cycle, with 30% new dysmenorrhea cases, since the beginning of the pandemic. Thus, COVID-19 has impacted the dysmenorrhea treatment market significantly.

Recent Development:

• In December 2020, Nua announced the release of a first-of-its-kind period pain relief solution called Cramps Comfort. Nua has released a revolutionary self-heating patch that can deliver up to 8 hours of heat to improve period discomfort.
• In 2022, Cora® debuted its fresh comfort-focused brand image, feel, and identity. Furthermore, company has expanded its range of products to fulfil the need of consumers.

Global Dysmenorrhea Treatment Market Scope

The global dysmenorrhea treatment market is segmented on the basis of type, treatment, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Primary Dysmenorrhea
• Secondary Dysmenorrhea

Treatment

• Hormonal Therapy
• Pain Reliever
• Surgery
• Others

End-Users

• Hospitals
• Homecare
• Speciality Centres
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Dysmenorrhea Treatment Market Regional Analysis/Insights

The dysmenorrhea treatment market is analyzed and market size insights and trends are provided by type, treatment, distribution channel and end-user as referenced above.

The major countries covered in the dysmenorrhea treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is expected to have the highest market growth due to the presence of key product manufacturers and increasing research and development activities.

Asia-Pacific dominates the market due to increased new research and developments on dysmenorrhea treatment market.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Dysmenorrhea Treatment Market Share Analysis

The dysmenorrhea treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to dysmenorrhea treatment market.

Key players operating in the dysmenorrhea treatment market include:

• Amgen Inc. (U.S.)
• Boehringer Ingelheim International GmbH. (Germany)
• Ipsen Pharma (France)
• Spectrum Pharmaceuticals, Inc. (U.S.)
• Takeda Pharmaceutical Company Limited. (Japan)
• BeyondSpring Inc. (U.S.)
• Apotex Inc. (Canada)
• Taj Pharmaceuticals, Limited. (India)
• Sanofi (France)
• Terramedic Incorporated (Philippines)
• Nua (India)
• Cora (India)